MAJOR MILESTONE ACHIEVEMENT IN AN ASSOCIATED COMPANY

2012.02.06

Jennerex and Lee's Pharmaceutical Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer

2011.11.30

Lee’s Pharm was honored at 2011’s Forbes Asia “Best Under A Billion” Award Ceremony

2011.11.22

Jennerex and Lee's Pharmaceutical Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer

2011.11.07

Submitted New Drug Application to the SFDA on Remodulin For Treatment of Pulmonary Arterial Hypertension

2011.09.12

Jennerex and Lee's Pharmaceutical Announce Publication of Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer

2011.09.09

Jennerex and Lee's Pharmaceutical Announce the Publicatiion of Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic PoxvirusJX 594 to Tumors

2011.09.01

Jennerex and Lee's Pharmaceutical Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma

2011.08.03

Completed Last Patient Follow-up in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy

2011.07.20

Jennerex and Lee's Pharmaceutical Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer

2011.05.23

Patients Enrollment completed in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy

2011.05.12

Lee’s Pharma Announced the New Drug Registration of Natulan® for Hodgkin’s Disease in China

2011.05.09

Lee’s Pharm Announced the Completion of Phase I Study for its first-in-class drug Declotana®

2011.04.18

Patients Enrollment completed in Clinical Study on Propiverine Hydrochloride Modified Release Capsules for treatment of Urinary Incontinence

2011.04.13

Powder Pharmaceuticals Incorporated Enters into Agreement with Health-Chem Diagnostics, LLC obtaining Exclusive Manufacturing and Marketing Rights for TD Glucose in PRC, Hong Kong and other Asian Countries

2011.03.04

Propionyl-L-Carnitine Clinical Study Meets Primary and Secondary Endpoint of Treating Peripheral Arterial Diseases

2011.02.14

Approval received to initiate clinical study for Trittico®

2011.01.05

Lee’s Pharmaceutical Enters into Agreement with CID S.r.l. obtaining Exclusive Distribution of PTCA Balloon Catheters, Chrono Carbostent and Optima DES Carbostent in China

2010.12.30

Lee’s Pharm Accredited “Hong Kong Outstanding Enterprises 2010”

2010.12.06

Grand Opening of Headquarters of Powder Pharmaceuticals

2010.10.29

Grand Opening of Powder Pharmaceuticals Incorporated

2010.09.22

Patients Enrollment completed in Clinical Study on Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases

2010.07.02

UNITED THERAPEUTICS AND LEE’S PHARMACEUTICAL SIGN REMODULIN DISTRIBUTION AGREEMENT FOR CHINA

2010.07.02

Lee’s Pharm Accredited “Asia’s Best Companies 2010 – (China) Best Small Cap” Ranked 2nd

2010.06.09

Best Small-cap Company

2010.06.07

Lee’s Pharmaceutical Trading Debut

2010.05.17

Warm congratulations to the successful listing of Lee’s Pharm on the Main Board

2010.05.17

RECORDATI AND LEESPHARM ANNOUNCE PARTNERSHIP FOR ZANIDIP® IN CHINA

2010.03.15

Obtained Registration Certificate for Medical Device of Veloderm® in China

2010.01.29

Obtained Renewal of Imported Drug License for Co-dergocrine Mesylate in China

2010.01.15

Obtained Renewal of Imported Drug License for Ferplex® Iron Proteinsuccinylate Oral Solution in China

2010.01.14

Distribution Agreement signed to market Lercanidipine tablets in Hong Kong and Macau

2009.12.31

JENNEREX AND LEE’S PHARMACEUTICALS ANNOUNCE PARTNERSHIP FOR JX-594 IN CHINA

2009.11.23

Phase I Clinical Study on Antiplatelet Thrombolysin injection

2009.11.06

Lee's Pharmaceutical Enters into Agreement with Nippon Shinyaku A Move To Accelerate Market Diversification in China

2009.03.02

Lee's Pharmaceutical Establishes New R&D Centre at the Hong Kong Science Park To Bolster the Group's R&D Capabilities

2008.12.17

Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.

2008.12.22

New Drug Approval for Eyprotor® (Protein-free Calf Blood Extract Eye-gel) in China

2008.05.13

LEE'S SIGNED COLLABORATION AGREEMENT WITH NOVELOS

2007.12.19

SIGMA-TAU STRENGTHENS ITS PARTICIPATION IN LEE'S PHARMACEUTICALS

2007.09.20

Exclusive Distribution Agreement Signed for Aloxi® injection in China

2007.08.09

Completed the Pharmacokinetic Study of HIBOR® (Bemiparin Sodium)

2007.06.25

Distribution Agreement Signed with Italfarmaco of Italy for Serestill® in China

2007.06.18

Important milestones achieved in Clinical Studies of Stent & Balloon Catheter

2007.06.15

New Indication Approved for Cervicitis for Yallaferon

2006.10.18

Marketing Approval for Slounase® (Hemocoagulase) in China

2006.09.22

Approval to initiate a Clinical Trial for Hibor

2006.06.23

Approval for Clinical Study on Antiplatelet Thrombolysin injection

2006.02.20

Distribution agreement signed to market Propiverine Hydrochloride

2006.02.20

New Product Launch in Hong Kong - HIBOR® (Bemiparin Sodium)

2005.12.20

Completion of the Study of Yallaferon® in Cervicitis Patients

2005.12.20

New Drug Approval for Hemocoagulase snake venom

2005.10.17

Distribution of HORUS®S Coronary Stent

2005.09.28

New Indication Approved for Yallaferon®

2005.09.07

Distribution Agreement to market Somatostatin

2005.06.15

Complete patients recruitment for Cervicitis

2005.06.08

Completion of the Clinical Study of Eye-gel

2005.05.09

Market Isosorbide Mononitrate in HK and China

2005.03.29

Progress in Clinical Study of Eye-gel

2005.03.16

Good progress in Clinical Study in Cervicitis

2005.02.04